IMMX NASDAQ
Credit Risk of going bust: lower than 73% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Immix Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.0M against a stock market value of $668.2M.
Distance to default 8.21 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $501K (short-term plus half of long-term), stock volatility 84.0%; Altman Z'' 26.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Los Angeles, CA 90064
US
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Adams Helen C. | A-Award | 6,250 | — | 2026-05-22 |
| Adams Helen C. | A-Award | 12,500 | $8.78 | 2026-05-22 |
| Ng Carey | A-Award | 6,250 | — | 2026-05-22 |
| Ng Carey | A-Award | 12,500 | $8.78 | 2026-05-22 |
| Marquet Magda | A-Award | 6,250 | — | 2026-05-22 |